サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1750810

医薬品受託製造・研究サービスの市場規模、シェア、動向分析レポート：サービス別、地域別、セグメント別予測、2025年～2030年

Pharmaceutical Contract Manufacturing And Research Services Market Size, Share & Trends Analysis Report By Service (Manufacturing, Research), By Region (North America, Europe, Asia Pacific, Latin America), And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.35円
医薬品受託製造・研究サービスの市場規模、シェア、動向分析レポート：サービス別、地域別、セグメント別予測、2025年～2030年
出版日: 2025年05月02日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

医薬品受託製造・研究サービス市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の医薬品受託製造・研究サービス市場規模は2030年までに3,952億3,000万米ドルに達すると予測され、2025年から2030年までのCAGRは6.9%で成長すると予測されています。

製薬会社は、インフラへの多額の設備投資を回避し、複雑な規制状況を乗り切るために、CMOやCDMOを活用するケースが増えています。この戦略的な動きにより、創薬や商品化といったコアコンピタンスにリソースを集中させることができます。また、専門化された医薬品受託機関により達成されるスケールメリットは、製造コストの削減にも貢献します。

特に生物製剤、バイオシミラー、HPAPI、個別化医療など、医薬品開発の複雑さが増しているため、受託サービス・プロバイダーは高度な能力と専門知識を必要としています。これらの組織は、効率的でコンプライアンスに適合した生産に不可欠な連続生産や高度なハンドリングシステムなどの最先端技術を保有していることが多いです。

慢性疾患の有病率の上昇や、特許切れに伴う手頃な価格のジェネリック医薬品やバイオシミラーの需要など、世界の健康動向も主要な成長促進要因です。厳しく進化する規制環境は、迅速な市場参入の必要性と相まって、製薬会社がCMOやCDMOの確立された専門知識を活用する動機となっています。アジア太平洋のようなコスト競争力のある地域への戦略的な地理的シフトや、包括的なソリューションを提供するCROとCDMOの統合モデルの出現は、この市場のダイナミックな成長を裏付けています。

医薬品受託製造・研究サービス市場レポートハイライト

  • ジェネリック医薬品、バイオシミラー医薬品、ワクチンの製造における規模とコスト効率の必要性が市場を牽引しています。
  • 受託製造業者は必要不可欠な能力、柔軟性、規制上のサポートを提供し、アジア太平洋地域の成長を促進しています。
  • 医薬品受託製造は、予測期間中に最速のCAGR 7.0％を記録すると予測されています。
  • 複雑な領域での研究開発の増加とCROの専門的な専門知識への需要は、高度な技術と複雑な規制への対応を通じて、国際共同治験におけるコストと時間の節約を提供します。
  • アジア太平洋地域の医薬品受託製造・研究サービス市場は、2024年の売上高シェアが40.0%を超え、世界市場を独占しました。これは、シンガポール、中国、インドのような新興経済諸国におけるアウトソーシングの増加に支えられ、製造能力が拡大し、CMOへの投資が活発化しているためです。
  • 2024年11月、ロンザ（スイス）はヴィスプにおけるバイオコンジュゲーション能力の大幅な拡大を発表しました。この投資には、増大する市場需要に対応するための1,200L製造スイート2室の増設が含まれます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 医薬品受託製造・研究サービス市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 医薬品受託製造・研究サービス市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 医薬品受託製造・研究サービス市場：サービス別推定・動向分析

  • サービス別セグメントダッシュボード
  • 医薬品受託製造・研究サービス市場：サービス別変動分析
  • 世界の医薬品受託製造・研究サービス市場規模と動向分析（サービス別、2018～2030年）
  • 製造業
    • API/バルク医薬品
    • 高度なドラッグデリバリー製剤
    • パッケージ
    • 最終投与製剤
  • 研究
    • 腫瘍学
    • ワクチン
    • 炎症と免疫学
    • 心臓病学
    • 神経科学
    • その他

第5章 医薬品受託製造・研究サービス市場：地域別推定・動向分析

  • 地域別市場ダッシュボード
  • 地域別市場シェア分析、2024年および2030年
  • 地域別医薬品受託製造・研究サービス市場：主なポイント
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第6章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • ベンダー情勢
    • Key company heat map analysis, 2024
  • 企業プロファイル
    • Catalent, Inc（Novo Holdings A/S）
    • PPD（Thermo Fisher Scientific Inc.）
    • AbbVie Inc.
    • Advent International, LP
    • Grifols
    • Dalton Pharma Services
    • Boehringer Ingelheim International GmbH
    • Lonza
図表

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global pharmaceutical contract manufacturing and research services market, by region, 2018 - 2030 (USD Million)
  • Table 3 Global pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 4 North America pharmaceutical contract manufacturing and research services market, by country, 2018 - 2030 (USD Million)
  • Table 5 North America pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 6 U.S. pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 7 Canada pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 8 Mexico pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 9 Europe pharmaceutical contract manufacturing and research services market, by country, 2018 - 2030 (USD Million)
  • Table 10 Europe pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 11 UK pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 12 Germany pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 13 France pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 14 Italy pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 15 Spain pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 16 Denmark pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 17 Sweden pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 18 Norway pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 19 Asia Pacific pharmaceutical contract manufacturing and research services market, by country, 2018 - 2030 (USD Million)
  • Table 20 Asia Pacific pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 21 China pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 22 Japan pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 23 India pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 24 Australia pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 25 South Korea pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 26 Thailand pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 27 Latin America pharmaceutical contract manufacturing and research services market, by country, 2018 - 2030 (USD Million)
  • Table 28 Latin America pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 29 Brazil pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 30 Argentina pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 31 MEA pharmaceutical contract manufacturing and research services market, by region, 2018 - 2030 (USD Million)
  • Table 32 MEA pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 33 South Africa pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 34 Saudi Arabia pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 35 UAE pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)
  • Table 36 Kuwait pharmaceutical contract manufacturing and research services market, by service, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Pharmaceutical contract manufacturing and research services market: market outlook
  • Fig. 10 Pharmaceutical contract manufacturing and research services competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 Pharmaceutical contract manufacturing and research services market driver impact
  • Fig. 16 Pharmaceutical contract manufacturing and research services market restraint impact
  • Fig. 17 Pharmaceutical contract manufacturing and research services market strategic initiatives analysis
  • Fig. 18 Pharmaceutical contract manufacturing and research services market: Service movement analysis
  • Fig. 19 Pharmaceutical contract manufacturing and research services market: Service outlook and key takeaways
  • Fig. 20 Manufacturing estimates and forecast, 2018 - 2030
  • Fig. 21 API/bulk drugs estimates and forecast, 2018 - 2030
  • Fig. 22 Advanced drug delivery formulations estimates and forecast, 2018 - 2030
  • Fig. 23 Packaging estimates and forecast, 2018 - 2030
  • Fig. 24 Finished dose formulations estimates and forecast, 2018 - 2030
  • Fig. 25 Solid estimates and forecast, 2018 - 2030
  • Fig. 26 Liquid estimates and forecast, 2018 - 2030
  • Fig. 27 Semi-solid formulations estimates and forecast, 2018 - 2030
  • Fig. 28 Research estimates and forecast, 2018 - 2030
  • Fig. 29 Oncology estimates and forecast, 2018 - 2030
  • Fig. 30 Vaccines estimates and forecast, 2018 - 2030
  • Fig. 31 Inflammation & immunology estimates and forecast, 2018 - 2030
  • Fig. 32 Cardiology estimates and forecast, 2018 - 2030
  • Fig. 33 Neuroscience estimates and forecast, 2018 - 2030
  • Fig. 34 Others estimates and forecast, 2018 - 2030
  • Fig. 35 Global pharmaceutical contract manufacturing and research services market: Regional movement analysis
  • Fig. 36 Global pharmaceutical contract manufacturing and research services market: Regional outlook and key takeaways
  • Fig. 37 North America market estimates and forecasts, 2018 - 2030
  • Fig. 38 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 39 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 40 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 41 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 42 UK market estimates and forecasts, 2018 - 2030
  • Fig. 43 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 44 France market estimates and forecasts, 2018 - 2030
  • Fig. 45 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 46 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 47 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 48 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 49 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 50 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 51 China market estimates and forecasts, 2018 - 2030
  • Fig. 52 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 53 India market estimates and forecasts, 2018 - 2030
  • Fig. 54 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 55 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 56 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 57 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 58 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 59 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 60 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 61 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 62 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 63 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 64 Kuwait market estimates and forecasts, 2018 - 2030
目次
Product Code: GVR-1-68038-924-1

Pharmaceutical Contract Manufacturing And Research Services Market Growth & Trends:

The global pharmaceutical contract manufacturing and research services market size is anticipated to reach USD 395.23 billion by 2030 and is projected to grow at a CAGR of 6.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. Pharmaceutical companies are increasingly leveraging CMOs and CDMOs to avoid substantial capital investments in infrastructure and navigate complex regulatory landscapes. This strategic move allows them to concentrate resources on core competencies like drug discovery and commercialization. The economies of scale achieved by specialized contract organizations further contribute to reduced production costs.

The escalating complexity of drug development, particularly in biologics, biosimilars, HPAPIs, and personalized medicine, necessitates the advanced capabilities and expertise readily available within contract service providers. These organizations often possess cutting-edge technologies such as continuous manufacturing and sophisticated handling systems, which prove vital for efficient and compliant production.

Global health trends, including the rising prevalence of chronic diseases and the demand for affordable generics and biosimilars following patent expirations, are also key growth drivers. The stringent and evolving regulatory environment, coupled with the imperative for faster market entry, incentivizes pharmaceutical companies to utilize the established expertise of CMOs and CDMOs. The strategic geographic shifts towards cost-competitive regions like Asia-Pacific and the emergence of integrated CRO-CDMO models offering comprehensive solutions underscore the dynamic growth of this market.

Pharmaceutical Contract Manufacturing And Research Services Market Report Highlights:

  • Based on service, pharmaceutical contract manufacturing services dominated the market with over 60.0% of the total revenue share in 2024, driven by the need for scale and cost efficiency in producing generics, biosimilars, and vaccines.
  • Contract manufacturers offer essential capacity, flexibility, and regulatory support, facilitating growth in regions like Asia-Pacific.
  • Pharmaceutical contract research services are projected to witness the fastest CAGR of 7.0% over the forecast period.
  • Increasing R&D in complex areas and the demand for CROs' specialized expertise offer cost and time savings in global trials through advanced technologies and navigating regulatory complexities.
  • The Asia Pacific pharmaceutical contract manufacturing and research services market dominated the global market with a revenue share of more than 40.0% in 2024, supported by increased outsourcing in developing economies like Singapore, China, and India, which have expanding manufacturing capabilities and significant CMO investments.
  • In November 2024, Lonza (Switzerland) announced a significant expansion of its bioconjugation capabilities in Visp. This investment includes adding two 1,200L manufacturing suites to meet increasing market demand.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Service
    • 1.2.2. Regional scope
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Service outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Pharmaceutical Contract Manufacturing And Research Services Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Pharmaceutical Contract Manufacturing And Research Services Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Pharmaceutical Contract Manufacturing And Research Services Market: Service Estimates & Trend Analysis

  • 4.1. Service Segment Dashboard
  • 4.2. Pharmaceutical Contract Manufacturing And Research Services Market: Service Movement Analysis
  • 4.3. Global Pharmaceutical Contract Manufacturing And Research Services Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
  • 4.4. Manufacturing
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. API/Bulk Drugs
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Advanced Drug Delivery Formulations
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Packaging
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Finished Dose Formulations
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.5.2. Solid
        • 4.4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.5.3. Liquid
        • 4.4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.5.4. Semi-solid Formulations
        • 4.4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Research
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2. Oncology
      • 4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3. Vaccines
      • 4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.4. Inflammation & Immunology
      • 4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.5. Cardiology
      • 4.5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.6. Neuroscience
      • 4.5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.7. Others
      • 4.5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Pharmaceutical Contract Manufacturing And Research Services Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Market Dashboard
  • 5.2. Regional Market Share Analysis, 2024 & 2030
  • 5.3. Pharmaceutical contract manufacturing and research services market by Region: Key Takeaways
  • 5.4. North America
    • 5.4.1. U.S.
      • 5.4.1.1. Key country dynamics
      • 5.4.1.2. Regulatory framework/ reimbursement structure
      • 5.4.1.3. Competitive scenario
      • 5.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Canada
      • 5.4.2.1. Key country dynamics
      • 5.4.2.2. Regulatory framework/ reimbursement structure
      • 5.4.2.3. Competitive scenario
      • 5.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Mexico
      • 5.4.3.1. Key country dynamics
      • 5.4.3.2. Regulatory framework/ reimbursement structure
      • 5.4.3.3. Competitive scenario
      • 5.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Europe
    • 5.5.1. UK
      • 5.5.1.1. Key country dynamics
      • 5.5.1.2. Regulatory framework/ reimbursement structure
      • 5.5.1.3. Competitive scenario
      • 5.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.2. Germany
      • 5.5.2.1. Key country dynamics
      • 5.5.2.2. Regulatory framework/ reimbursement structure
      • 5.5.2.3. Competitive scenario
      • 5.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.3. France
      • 5.5.3.1. Key country dynamics
      • 5.5.3.2. Regulatory framework/ reimbursement structure
      • 5.5.3.3. Competitive scenario
      • 5.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.4. Italy
      • 5.5.4.1. Key country dynamics
      • 5.5.4.2. Regulatory framework/ reimbursement structure
      • 5.5.4.3. Competitive scenario
      • 5.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.5. Spain
      • 5.5.5.1. Key country dynamics
      • 5.5.5.2. Regulatory framework/ reimbursement structure
      • 5.5.5.3. Competitive scenario
      • 5.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.6. Denmark
      • 5.5.6.1. Key country dynamics
      • 5.5.6.2. Regulatory framework/ reimbursement structure
      • 5.5.6.3. Competitive scenario
      • 5.5.6.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.7. Sweden
      • 5.5.7.1. Key country dynamics
      • 5.5.7.2. Regulatory framework/ reimbursement structure
      • 5.5.7.3. Competitive scenario
      • 5.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.8. Norway
      • 5.5.8.1. Key country dynamics
      • 5.5.8.2. Regulatory framework/ reimbursement structure
      • 5.5.8.3. Competitive scenario
      • 5.5.8.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Asia Pacific
    • 5.6.1. China
      • 5.6.1.1. Key country dynamics
      • 5.6.1.2. Regulatory framework/ reimbursement structure
      • 5.6.1.3. Competitive scenario
      • 5.6.1.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.2. Japan
      • 5.6.2.1. Key country dynamics
      • 5.6.2.2. Regulatory framework/ reimbursement structure
      • 5.6.2.3. Competitive scenario
      • 5.6.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.3. India
      • 5.6.3.1. Key country dynamics
      • 5.6.3.2. Regulatory framework/ reimbursement structure
      • 5.6.3.3. Competitive scenario
      • 5.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.4. Australia
      • 5.6.4.1. Key country dynamics
      • 5.6.4.2. Regulatory framework/ reimbursement structure
      • 5.6.4.3. Competitive scenario
      • 5.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.5. South Korea
      • 5.6.5.1. Key country dynamics
      • 5.6.5.2. Regulatory framework/ reimbursement structure
      • 5.6.5.3. Competitive scenario
      • 5.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.6. Thailand
      • 5.6.6.1. Key country dynamics
      • 5.6.6.2. Regulatory framework/ reimbursement structure
      • 5.6.6.3. Competitive scenario
      • 5.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Latin America
    • 5.7.1. Brazil
      • 5.7.1.1. Key country dynamics
      • 5.7.1.2. Regulatory framework/ reimbursement structure
      • 5.7.1.3. Competitive scenario
      • 5.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.2. Argentina
      • 5.7.2.1. Key country dynamics
      • 5.7.2.2. Regulatory framework/ reimbursement structure
      • 5.7.2.3. Competitive scenario
      • 5.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. MEA
    • 5.8.1. South Africa
      • 5.8.1.1. Key country dynamics
      • 5.8.1.2. Regulatory framework/ reimbursement structure
      • 5.8.1.3. Competitive scenario
      • 5.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.2. Saudi Arabia
      • 5.8.2.1. Key country dynamics
      • 5.8.2.2. Regulatory framework/ reimbursement structure
      • 5.8.2.3. Competitive scenario
      • 5.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.3. UAE
      • 5.8.3.1. Key country dynamics
      • 5.8.3.2. Regulatory framework/ reimbursement structure
      • 5.8.3.3. Competitive scenario
      • 5.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.4. Kuwait
      • 5.8.4.1. Key country dynamics
      • 5.8.4.2. Regulatory framework/ reimbursement structure
      • 5.8.4.3. Competitive scenario
      • 5.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Company/Competition Categorization
  • 6.3. Vendor Landscape
    • 6.3.1. Key company heat map analysis, 2024
  • 6.4. Company Profiles
    • 6.4.1. Catalent, Inc (Novo Holdings A/S)
      • 6.4.1.1. Company overview
      • 6.4.1.2. Financial performance
      • 6.4.1.3. Product benchmarking
      • 6.4.1.4. Strategic initiatives
    • 6.4.2. PPD (Thermo Fisher Scientific Inc.)
      • 6.4.2.1. Company overview
      • 6.4.2.2. Financial performance
      • 6.4.2.3. Product benchmarking
      • 6.4.2.4. Strategic initiatives
    • 6.4.3. AbbVie Inc.
      • 6.4.3.1. Company overview
      • 6.4.3.2. Financial performance
      • 6.4.3.3. Product benchmarking
      • 6.4.3.4. Strategic initiatives
    • 6.4.4. Advent International, L.P.
      • 6.4.4.1. Company overview
      • 6.4.4.2. Financial performance
      • 6.4.4.3. Product benchmarking
      • 6.4.4.4. Strategic initiatives
    • 6.4.5. Grifols
      • 6.4.5.1. Company overview
      • 6.4.5.2. Financial performance
      • 6.4.5.3. Product benchmarking
      • 6.4.5.4. Strategic initiatives
    • 6.4.6. Dalton Pharma Services
      • 6.4.6.1. Company overview
      • 6.4.6.2. Financial performance
      • 6.4.6.3. Product benchmarking
      • 6.4.6.4. Strategic initiatives
    • 6.4.7. Boehringer Ingelheim International GmbH
      • 6.4.7.1. Company overview
      • 6.4.7.2. Financial performance
      • 6.4.7.3. Product benchmarking
      • 6.4.7.4. Strategic initiatives
    • 6.4.8. Lonza
      • 6.4.8.1. Company overview
      • 6.4.8.2. Financial performance
      • 6.4.8.3. Product benchmarking
      • 6.4.8.4. Strategic initiatives